Dirk De Ruysscher

Summary

Affiliation: University Hospital Maastricht
Country: The Netherlands

Publications

  1. ncbi request reprint Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer
    Suresh Senan
    Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Radiother Oncol 71:139-46. 2004
  2. ncbi request reprint Critical review of PET-CT for radiotherapy planning in lung cancer
    Suresh Senan
    Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, Post Box 7057, 1007 MB Amsterdam, The Netherlands
    Crit Rev Oncol Hematol 56:345-51. 2005
  3. ncbi request reprint Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients
    D De Ruysscher
    Department of Radiotherapy, Maastro Clinic, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Ann Oncol 18:909-16. 2007
  4. doi request reprint Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study
    Dirk De Ruysscher
    Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Center, Maastricht, The Netherlands
    Radiother Oncol 91:415-20. 2009
  5. pmc Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology
    Patsuree Cheebsumon
    Department of Radiology and Nuclear Medicine, VU University Medical Center, PO Box 7057, Amsterdam, 1007MB, The Netherlands
    EJNMMI Res 2:56. 2012
  6. doi request reprint State of the art radiation therapy for lung cancer 2012: a glimpse of the future
    Dirk De Ruysscher
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Clin Lung Cancer 14:89-95. 2013
  7. doi request reprint Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study
    Dirk De Ruysscher
    Department of Radiation Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    Radiother Oncol 102:228-33. 2012
  8. doi request reprint Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?
    D De Ruysscher
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center Maastricht, Maastricht, The Netherlands
    Strahlenther Onkol 188:564-7. 2012
  9. doi request reprint Charged particles in radiotherapy: a 5-year update of a systematic review
    Dirk De Ruysscher
    Department of Radiation Oncology, MAASTRO, Maastricht University Medical Center, The Netherlands
    Radiother Oncol 103:5-7. 2012
  10. doi request reprint PET scans in radiotherapy planning of lung cancer
    Dirk De Ruysscher
    Maastricht University Medical Center, Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands
    Lung Cancer 75:141-5. 2012

Detail Information

Publications87

  1. ncbi request reprint Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer
    Suresh Senan
    Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Radiother Oncol 71:139-46. 2004
    ..To review the literature on techniques used in high-dose radiotherapy of lung cancer in order to develop recommendations for clinical practice and for use in research protocols...
  2. ncbi request reprint Critical review of PET-CT for radiotherapy planning in lung cancer
    Suresh Senan
    Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, Post Box 7057, 1007 MB Amsterdam, The Netherlands
    Crit Rev Oncol Hematol 56:345-51. 2005
    ..Data on the role of PET scans for radiotherapy planning for limited stage small-cell lung cancer is limited, although the incorporation of FDG-PET positive regions would appear to be reasonable...
  3. ncbi request reprint Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients
    D De Ruysscher
    Department of Radiotherapy, Maastro Clinic, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Ann Oncol 18:909-16. 2007
    ..We therefore identified factors associated with the occurrence of acute dysphagia in lung cancer patients receiving radiotherapy alone or combined with chemotherapy...
  4. doi request reprint Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study
    Dirk De Ruysscher
    Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Center, Maastricht, The Netherlands
    Radiother Oncol 91:415-20. 2009
    ..As Radiation-Induced Lung Toxicity (RILT) is dose-limiting for radiotherapy (RT) of lung cancer and current parameters are only moderately associated with RILT, we sought for novel parameters associated with RILT...
  5. pmc Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology
    Patsuree Cheebsumon
    Department of Radiology and Nuclear Medicine, VU University Medical Center, PO Box 7057, Amsterdam, 1007MB, The Netherlands
    EJNMMI Res 2:56. 2012
    ..abstract:..
  6. doi request reprint State of the art radiation therapy for lung cancer 2012: a glimpse of the future
    Dirk De Ruysscher
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Clin Lung Cancer 14:89-95. 2013
    ....
  7. doi request reprint Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study
    Dirk De Ruysscher
    Department of Radiation Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    Radiother Oncol 102:228-33. 2012
    ..Individualised, isotoxic, accelerated radiotherapy (INDAR) allows the delivery of high biological radiation doses, but the long-term survival associated with this approach is unknown...
  8. doi request reprint Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?
    D De Ruysscher
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center Maastricht, Maastricht, The Netherlands
    Strahlenther Onkol 188:564-7. 2012
    ..A strong association between neutropenia and oesophagitis was previously shown, but external validation and further elucidation of the possible mechanisms are lacking...
  9. doi request reprint Charged particles in radiotherapy: a 5-year update of a systematic review
    Dirk De Ruysscher
    Department of Radiation Oncology, MAASTRO, Maastricht University Medical Center, The Netherlands
    Radiother Oncol 103:5-7. 2012
    ..In our view, the aim should be to build enough proton therapy facilities with interest in research to further improve the treatment and to run the needed clinical trials...
  10. doi request reprint PET scans in radiotherapy planning of lung cancer
    Dirk De Ruysscher
    Maastricht University Medical Center, Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands
    Lung Cancer 75:141-5. 2012
    ..However, care must be taken to avoid a variety of technical pitfalls and specific education is necessary, for clinicians and physicists alike...
  11. doi request reprint Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer
    Dirk De Ruysscher
    Maastricht University Medical Center, Department of Radiation Oncology Maastro Clinic, GROW Research Institute, Maastricht, The Netherlands
    Radiother Oncol 91:353-9. 2009
    ..To determine what the influence is of dyspnea (CTCAE3.0) before high-dose radiotherapy (RT) on the incidence and severity of subsequent lung toxicity in patients with non-small cell lung cancer (NSCLC)...
  12. doi request reprint PET scans in radiotherapy planning of lung cancer
    Dirk De Ruysscher
    Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Center, GROW Research Institute, The Netherlands
    Radiother Oncol 96:335-8. 2010
    ..In limited-disease small cell lung cancer, the role of FDG-PET is emerging...
  13. doi request reprint First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II
    Dirk De Ruysscher
    Department of Radiotherapy Maastro Clinic, Maastricht University Medical Center, The Netherlands
    Radiother Oncol 97:36-9. 2010
    ..Identifying the most radiosensitive patient group would have huge clinical implications...
  14. doi request reprint Treatment of limited disease small cell lung cancer
    Dirk De Ruysscher
    Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Medical Center Maastricht, Maastricht, The Netherlands
    Front Radiat Ther Oncol 42:173-9. 2010
    ..With this treatment, 5-year survival rates of 25% can be achieved in patients with LD-SCLC...
  15. ncbi request reprint HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer
    Dirk De Ruysscher
    Department of Radiation Oncology, University Hospital Maastricht, GROW, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 71:132-8. 2008
    ..To determine the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer (NSCLC)...
  16. doi request reprint Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study
    Dirk De Ruysscher
    Department of Radiation Oncology, Maastro Clinic, Maastricht University Medical Center, Maastricht, The Netherlands
    Radiother Oncol 93:389-95. 2009
    ..Improved local tumor control (LC) improves survival of patients with non-small cell lung cancer (NSCLC). We estimated the capability of surgical and non-surgical options to improve LC further in this disease...
  17. doi request reprint PET-CT in radiotherapy for lung cancer
    Dirk De Ruysscher
    Department of Radiotherapy Maastro Clinic, GROW Research Institute, Maastricht University Medical Center, Maastricht, The Netherlands
    Methods Mol Biol 727:53-8. 2011
    ..g., know patterns of tumor spread according to pathological studies, knowledge of endoscopic findings, and other tumor and patient factors) to come to target volume definitions that have proven their clinical efficacy...
  18. doi request reprint Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study
    D De Ruysscher
    Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Medical Center Maastricht, Maastricht, The Netherlands
    Ann Oncol 20:98-102. 2009
    ..The purpose of this prospective study was to get insight in what proportion of patients with locally advanced lung cancer would be suitable for concurrent chemoradiation...
  19. ncbi request reprint Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial
    Dirk De Ruysscher
    Maastro Clinic, Maastricht, The Netherlands
    Radiother Oncol 80:307-12. 2006
    ..To evaluate the patterns of recurrence when elective node irradiation was omitted in patients with limited disease small cell lung cancer (LD-SCLC)...
  20. ncbi request reprint High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancer
    D De Ruysscher
    Department of Radiation Oncology, Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    Minerva Chir 66:341-5. 2011
    ..Early results of INDAR with concurrent chemotherapy or with cetuximab are promising...
  21. doi request reprint European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer
    Dirk De Ruysscher
    Maastricht University Medical Center, GROW Research Institute, Department of Radiation Oncology Maastro Clinic, Dr Tanslaan 12, NL 6229 ET Maastricht, The Netherlands
    J Clin Oncol 28:5301-10. 2010
    ..To derive recommendations for routine practice and clinical trials for techniques used in high-dose, high-precision thoracic radiotherapy for lung cancer...
  22. ncbi request reprint Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer
    Dirk De Ruysscher
    Department of Radiotherapy, University Hospital Maastricht, University Maastricht, Groel en Ontwikkeling, The Netherlands
    J Clin Oncol 24:1057-63. 2006
    ..To identify time factors for combined chemotherapy and radiotherapy predictive for long-term survival of patients with limited-disease small-cell lung cancer (LD-SCLC)...
  23. ncbi request reprint Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer
    D De Ruysscher
    Department of Radiotherapy, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Ann Oncol 17:543-52. 2006
    ..We undertook a systematic review and literature-based meta-analysis to determine whether the timing of chest radiotherapy may influence the survival of patients with limited-stage small-cell lung cancer (LS-SCLC)...
  24. ncbi request reprint Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study
    Dirk De Ruysscher
    Department of Radiation Oncology MAASTRO, Maastricht, The Netherlands
    Radiother Oncol 77:5-10. 2005
    ..To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer...
  25. ncbi request reprint Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study
    Dirk De Ruysscher
    Maastro Clinic, and Department of Radiation Oncology, University Hospital Maastricht, p a Henri Dunantstraat 5, NL 6419 PC Heerlen, The Netherlands
    Int J Radiat Oncol Biol Phys 62:988-94. 2005
    ..To evaluate the patterns of recurrence when selective mediastinal node irradiation based on FDG-PET scan data is used in patients with non-small-cell lung cancer (NSCLC)...
  26. ncbi request reprint Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial
    Dirk De Ruysscher
    Maastro Clinic, Maastricht, The Netherlands
    Radiother Oncol 84:23-5. 2007
    ..None of the endpoints differed significantly between both groups. However, due to the limited number of patients, no definitive conclusions can be drawn...
  27. doi request reprint Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer
    Bart Reymen
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 85:1319-24. 2013
    ..In non-small cell lung cancer, gross tumor volume (GTV) influences survival more than other risk factors. This could also apply to small cell lung cancer...
  28. doi request reprint Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study
    Judith van Loon
    Department of Radiation Oncology, Maastro Clinic, GROW Research Institute, Maastricht University Medical Centre, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 77:329-36. 2010
    ..To evaluate the results of selective nodal irradiation on basis of (18)F-deoxyglucose positron emission tomography (PET) scans in patients with limited-disease small-cell lung cancer (LD-SCLC) on isolated nodal failure...
  29. ncbi request reprint Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer
    Geert Bosmans
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 71:139-44. 2008
    ..This study describes the time trends in nodal computed tomography (CT) volume and motion for patients with locally advanced non-small-cell lung cancer (NSCLC)...
  30. doi request reprint Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings
    Marco H M Janssen
    Department of Radiation Oncology MAASTRO, University Medical Centre Maastricht, Maastricht, The Netherlands
    Radiother Oncol 94:151-5. 2010
    ..The purpose of this study was to prospectively investigate metabolic changes of rectal tumors after 1 week of treatment of either radiochemotherapy (28 x 1.8 Gy+Capecitabine) (RCT) or hypofractionated radiotherapy (5 x 5 Gy) alone (RT)...
  31. doi request reprint Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study
    Judith van Loon
    Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Medical Centre, Dr Tanslaan 12, NL 6229 ET Maastricht, The Netherlands
    Eur J Cancer 45:588-95. 2009
    ..Because the accuracy of (18)FDG-PET-CT is superior to CT, we hypothesised that FDG-PET-CT scans 3 months post-treatment could lead to early detection of progressive disease (PD) amenable for radical treatment...
  32. doi request reprint Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study
    Judith van Loon
    Department of Radiation Oncology, Maastricht University Medical Centre, The Netherlands
    Radiother Oncol 99:172-5. 2011
    ..The purpose of the current study was to evaluate whether CT or FDG metabolic response early after the start of chemotherapy, but before the beginning of chest RT, is predictive for survival in SCLC...
  33. doi request reprint Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan
    Hugo J W L Aerts
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University, The Netherlands
    Radiother Oncol 91:386-92. 2009
    ..We hypothesized that areas within the tumour with a high pre-radiation (18)F-deoxyglucose (FDG) uptake, could identify residual metabolic-active areas, ultimately enabling selective-boosting of tumour sub-volumes...
  34. doi request reprint 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study
    Judith van Loon
    Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Hospital Maastricht, Maastricht, The Netherlands
    Radiother Oncol 87:49-54. 2008
    ..To investigate the influence of selective irradiation of 18FDG-PET positive mediastinal nodes on radiation fields and normal tissue exposure in limited disease small cell lung cancer (LD-SCLC)...
  35. doi request reprint 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation
    Judith van Loon
    Department of Radiation Oncology Maastro Clinic, GROW Research Institute, Maastricht University Medical Centre, Maastricht, The Netherlands
    Eur J Cancer 46:110-9. 2010
    ..Here, we report on the economic evaluation of this study...
  36. doi request reprint Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy
    Cary Dehing-Oberije
    Department of Radiotherapy, Maastro Clinic, Research Institute of Growth and Development, University Hospital Maastricht, University Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 74:355-62. 2009
    ..The objective of this study was to develop and validate a prediction model for survival of NSCLC patients, treated with chemoradiotherapy...
  37. ncbi request reprint Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study
    Antoinet van Der Wel
    Maastro Clinic, University Hospital Maastricht, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 61:649-55. 2005
    ....
  38. doi request reprint [¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients
    Steven F Petit
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 81:698-705. 2011
    ..The relationship between pretreatment [(18)F]fluorodeoxyglucose ([(18)F]FDG) uptake in the lungs (as a surrogate for inflammation) and the delivered radiation dose and radiation-induced lung toxicity (RILT) was investigated...
  39. doi request reprint Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study
    Angela van Baardwijk
    Department of Radiation Oncology MAASTRO, GROW Research Institute, University Hospital Maastricht, Dr Tanslaan 12, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 71:1394-401. 2008
    ..We report first results of a prospective feasibility trial...
  40. doi request reprint Tumor delineation based on time-activity curve differences assessed with dynamic fluorodeoxyglucose positron emission tomography-computed tomography in rectal cancer patients
    Marco H M Janssen
    Department of Radiation Oncology MAASTRO, Research Institute GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 73:456-65. 2009
    ....
  41. doi request reprint Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer
    Erik Roelofs
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
    J Thorac Oncol 7:165-76. 2012
    ..The hypothesis is that proton radiotherapy decreases the dose and the volume of irradiated normal tissues even when escalating to the maximum tolerable dose of one or more of the organs at risk (OAR)...
  42. doi request reprint Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study
    Steven F Petit
    Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
    Radiother Oncol 91:393-8. 2009
    ..To characterize the relationship between pre-radiotherapy (18)Fluorodeoxyglucose (FDG) uptake in a tumour voxel, radiation dose and the probability to achieve metabolic control in the tumour voxel after radiotherapy...
  43. ncbi request reprint Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy
    Cary Dehing-Oberije
    Department of Radiotherapy, University Hospital Maastricht, University Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 70:1039-44. 2008
    ..In this study, we investigated the prognostic value of tumor volume and N status, assessed by using fluorodeoxyglucose-positron emission tomography (PET)...
  44. ncbi request reprint Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients
    Angela van Baardwijk
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Radiother Oncol 82:145-52. 2007
    ..We investigated changes in FDG uptake during fractionated radiotherapy in relation to metabolic response with the ultimate aim to adapt treatment according to early response...
  45. ncbi request reprint PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes
    Angela van Baardwijk
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 68:771-8. 2007
    ....
  46. doi request reprint Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study
    Angela van Baardwijk
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Radiother Oncol 87:55-8. 2008
    ..For this purpose we used an ex-vivo model. The procedure was feasible in all operated patients. We have shown that this method is suitable for correlating intra-tumour heterogeneity in tracer uptake with histology...
  47. ncbi request reprint Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study
    Geert Bosmans
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 66:748-53. 2006
    ..The aim of this study was to investigate the change in tumor volume, motion, and breathing frequency during a course of radiotherapy, for locally advanced non-small-cell lung cancer...
  48. ncbi request reprint Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)
    Dirk De Ruysscher
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, University Medical Centre Maastricht, Maastricht, The Netherlands
    J Thorac Oncol 7:1547-55. 2012
    ....
  49. doi request reprint Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study
    Rinus Wanders
    Department of Radiation Oncology, Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    Eur J Cancer 47:2691-7. 2011
    ..There is little data on the survival of elderly patients with stage III non-small cell lung cancer (NSCLC)...
  50. doi request reprint Should patient setup in lung cancer be based on the primary tumor? An analysis of tumor coverage and normal tissue dose using repeated positron emission tomography/computed tomography imaging
    Wouter van Elmpt
    Department of Radiation Oncology, MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 82:379-85. 2012
    ..Evaluation of the dose distribution for lung cancer patients using a patient setup procedure based on the bony anatomy or the primary tumor...
  51. doi request reprint Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial
    Angela van Baardwijk
    Department of Radiation Oncology MAASTRO, GROW Research Institute University Hospital Maastricht, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 71:1103-10. 2008
    ..We investigated the theoretical gain in the estimated tumor control probability (TCP) using an individualized maximal tolerable dose (MTD) prescription, for both conventional and accelerated fractionation schemes...
  52. doi request reprint The use of FDG-PET to target tumors by radiotherapy
    Guido Lammering
    Maastro Clinic, Radiation Oncology, Maastricht, The Netherlands
    Strahlenther Onkol 186:471-81. 2010
    ..Besides for staging purposes, FDG-PET is not recommended for routine radiotherapy delineation purposes. It should be emphasized that using PET is only safe when adhering to strictly standardized protocols...
  53. doi request reprint Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients
    Cary Dehing-Oberije
    Department of Radiotherapy, Maastricht University Medical Center, University Maastricht, Maastro Clinic, GROW, The Netherlands
    Radiother Oncol 97:455-61. 2010
    ..Therefore, we have developed and validated a nomogram to predict this side-effect. In addition, clinical usefulness was assessed by comparing model predictions to physicians' predictions...
  54. doi request reprint Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review
    Angela van Baardwijk
    Maastricht University Medical Centre, The Netherlands
    Radiother Oncol 105:145-9. 2012
    ..We investigated the doses at the edge of the PTV and correlated this with local tumour control with the aim to shed light on the radiation dose needed to eradicate stage I NSCLC...
  55. doi request reprint Health-related quality of life in patients surviving non-small cell lung cancer
    Janneke P C Grutters
    Department of Health Organization, Policy and Economics, Caphri Research Institute, Maastricht University, Maastricht, The Netherlands
    Thorax 65:903-7. 2010
    ..In this study, the EQ-5D was used to assess HRQoL in survivors of non-small cell lung cancer (NSCLC). The influence of tumour stage, adverse events, initial treatment and presence of recurrence was examined...
  56. doi request reprint Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation
    Hugo J W L Aerts
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
    Lung Cancer 75:73-6. 2012
    ..Therefore, a pre-radiotherapy FDG-PET-CT scan can potentially be used for radiotherapy dose redistribution...
  57. doi request reprint The importance of patient characteristics for the prediction of radiation-induced lung toxicity
    Cary Dehing-Oberije
    Department of Radiotherapy, University Maastricht, GROW, Maastricht, The Netherlands
    Radiother Oncol 91:421-6. 2009
    ..We investigated the predictive value of patient characteristics in combination with established dosimetric parameters...
  58. doi request reprint Volume or position changes of primary lung tumor during (chemo-)radiotherapy cannot be used as a surrogate for mediastinal lymph node changes: the case for optimal mediastinal lymph node imaging during radiotherapy
    Wouter van Elmpt
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 79:89-95. 2011
    ..The purpose of this study was to investigate the relationship between the positional and volumetric changes in primary tumors and the involved LN during (chemo)radiotherapy treatment of non-small-cell lung cancer patients...
  59. doi request reprint Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer
    Angela van Baardwijk
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Eur J Cancer 48:2339-46. 2012
    ..We therefore performed a phase II trial (clinicaltrials.gov; NCT00572325) investigating the same strategy in concurrent chemo-radiation in stage III NSCLC...
  60. ncbi request reprint The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning
    Angela van Baardwijk
    University of Maastricht, GROW Research Institute, Maastricht, The Netherlands
    Cancer Treat Rev 32:245-60. 2006
    ..In most other tumour sites not enough data are currently available to draw definitive conclusions about the role of PET in radiation treatment planning...
  61. doi request reprint Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT0
    Cary Dehing-Oberije
    Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 81:360-8. 2011
    ..The hypothesis of this prospective study was that blood biomarkers related to hypoxia, inflammation, and tumor load would have an added prognostic value for predicting survival...
  62. doi request reprint Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?
    Roy F A Vliegen
    Department of Radiology, University Hospital Maastricht, Maastricht, The Netherlands
    Strahlenther Onkol 184:457-64. 2008
    ..So far, MRI and CT have failed to provide such information. Therefore, the value of a combined FDG-PET/CT in predicting tumor clearance of the mesorectal fascia (MRF) was determined...
  63. ncbi request reprint The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer
    Angela van Baardwijk
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Dr Tanslaan 12, 6229 ET Maastricht, The Netherlands
    Eur J Cancer 43:1392-8. 2007
    ..9% versus 62.5%, p=0.025), than tumours with a low SUV(max). No significant difference was found in the expression of CAIX, Ki-67 and GLUT-3. This study supports preclinical data that hypoxia is associated with a higher uptake of FDG...
  64. doi request reprint PET imaging of hypoxia using [18F]HX4: a phase I trial
    Judith van Loon
    Department of Radiation Oncology Maastro Clinic, GROW School of Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Eur J Nucl Med Mol Imaging 37:1663-8. 2010
    ..In this phase I trial, we aimed to determine the toxicity of [(18)F]HX4, a member of the 2-nitroimidazole family, at different dose levels. The secondary aim was to analyse image quality related to the HX4 dose and the timing of imaging...
  65. doi request reprint Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer
    Judith van Loon
    Maastricht University Medical Centre, Department of Radiation Oncology, Maastro Clinic, GROW Research Institute, The Netherlands
    Cancer Treat Rev 37:331-43. 2011
    ..Tracers other than (18)FDG are promising for treatment response assessment and the visualization of intra-tumor heterogeneity, but more research is needed before they can be clinically implemented...
  66. doi request reprint FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study
    Jos J Jager
    Maastro Clinic, Department of Radiation Oncology, 6202 NA Maastricht, The Netherlands
    Acta Oncol 49:185-91. 2010
    ..To determine the additional value of FDG-PET-CT as compared to conventional staging (CS) in high-risk breast cancer patients...
  67. ncbi request reprint An "in silico" clinical trial comparing free breathing, slow and respiration correlated computed tomography in lung cancer patients
    Geert Bosmans
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
    Radiother Oncol 81:73-80. 2006
    ..To determine which method of internal target volume (ITV) definition based on a respiration correlated CT (RCCT) allows optimal tumor coverage...
  68. doi request reprint The integration of PET-CT scans from different hospitals into radiotherapy treatment planning
    Michel Ollers
    Department of Radiation Oncology MAASTRO, University Hospital Maastricht, Maastricht, The Netherlands
    Radiother Oncol 87:142-6. 2008
    ..To integrate PET-CT scans from different hospitals into radiotherapy treatment planning...
  69. doi request reprint High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL
    Madelon Pijls-Johannesma
    Department of Radiation Oncology Maastro Clinic, Maastricht, The Netherlands
    Radiother Oncol 91:443-8. 2009
    ..The purpose of this study was to investigate the evolution of quality of life (QoL) in patients with lung cancer, selected for curative radiotherapy (RT) or chemo-RT...
  70. doi request reprint Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study
    Hugo J W L Aerts
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, University Hospital Maastricht, Dr Tanslaan 12, Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 71:1402-7. 2008
    ..To do this, it is critical to know whether the location of these high FDG uptake patterns within the tumor remain stable during radiotherapy (RT)...
  71. ncbi request reprint Palliative chest irradiation in sitting position in patients with bulky advanced lung cancer
    Cindy Duisters
    Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, The Netherlands
    Radiother Oncol 79:285-7. 2006
    ..The reproducibility of the sitting position was high and all ten patients preferred this position over lying down. In selected patients who are unable to lie down, palliative irradiation in a sitting position may be an option...
  72. pmc Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review
    Madelon Pijls-Johannesma
    Maastricht Radiation Oncology MAASTRO Clinic, Dr Tanslaan 12, 6229 ET Maastricht, The Netherlands
    Oncologist 15:93-103. 2010
    ..In this review, we searched for clinical evidence to justify implementation of particle therapy as standard treatment in lung cancer...
  73. doi request reprint Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis
    Janneke P C Grutters
    Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands
    Radiother Oncol 95:32-40. 2010
    ..To provide a comparison between radiotherapy with photons, protons and carbon-ions in the treatment of Non-Small-Cell Lung Cancer (NSCLC), performing a meta-analysis of observational studies...
  74. pmc Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours
    Wouter van Elmpt
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Dr Tanslaan 12, NL 6229 ET Maastricht, The Netherlands
    Eur J Nucl Med Mol Imaging 38:843-55. 2011
    ..We investigated the added value of a new respiratory amplitude-based PET reconstruction method called optimal gating (OG) with the aim of providing accurate image quantification in lung cancer...
  75. doi request reprint 3D dose delivery verification using repeated cone-beam imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancer
    Wouter van Elmpt
    Department of Radiation Oncology MAASTRO, Maastricht University Medical Centre, The Netherlands
    Radiother Oncol 94:188-94. 2010
    ..To implement a 3D dose verification procedure, based on in-room cone-beam CT imaging and portal dosimetry, for lung cancer patients treated with stereotactic body radiotherapy (SBRT)...
  76. doi request reprint A systematic methodology review of phase I radiation dose escalation trials
    Madelon Pijls-Johannesma
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Radiother Oncol 95:135-41. 2010
    ..The purpose of this review is to evaluate the methodology used in published phase I radiotherapy (RT) dose escalation trials. A specific emphasis was placed on the frequency of reporting late complications as endpoint...
  77. doi request reprint The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer
    Philippe Lambin
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    Radiother Oncol 96:145-52. 2010
    ..The administration of these complicated dose distributions requires a quality assurance procedure that can evaluate the treatment delivery and, if necessary, adapt the treatment plan during radiotherapy...
  78. ncbi request reprint Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients
    Ludy C H W Lutgens
    Department of Radiation Oncology MAASTRO, University Hospital Maastricht, Maastricht University, Dr Tanslan 12, 6229 ET Maastricht, The Netherlands
    Int J Radiat Oncol Biol Phys 60:275-85. 2004
    ..Our objective was to evaluate the feasibility of citrulline as a marker for radiation-induced small-intestinal mucosal atrophy in patients during and after abdominal fractionated radiotherapy...
  79. doi request reprint Prediction of residual metabolic activity after treatment in NSCLC patients
    Emmanuel Rios Velazquez
    Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
    Acta Oncol 49:1033-9. 2010
    ..We report on the development of a pre-treatment prediction model for metabolic response using patient, tumor and treatment factors...
  80. doi request reprint Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer
    Angela van Baardwijk
    Department of RadiationOncology MAASTRO, GROWResearch Institute, Maastricht UniversityMedical Center, Maastricht
    J Clin Oncol 28:1380-6. 2010
    ..Here, we report the mature results of a prospective, single-arm study that used this individualized tolerable dose approach...
  81. ncbi request reprint Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
    Madelon Pijls-Johannesma
    Maastro Clinic, University Hospital, Dr Tanslaan 12, 6229 ET Maastricht, The Netherlands
    Cancer Treat Rev 33:461-73. 2007
    ..We undertook a systematic review and literature-based meta-analysis to determine whether the timing of chest radiotherapy may influence the survival of patients with limited stage small cell lung cancer (LS-SCLC)...
  82. ncbi request reprint Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey
    Dirk De Ruysscher
    University Hospital Maastricht, Department of Radiation Oncology, Dr Tanslaan 12, NL 6229 ET Maastricht, The Netherlands
    Radiother Oncol 68:299-302. 2003
    ....
  83. ncbi request reprint Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement
    Cécile Le Péchoux
    J Clin Oncol 25:e10-1. 2007
  84. ncbi request reprint Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients
    Jonathan Orban de Xivry
    Communications and Remote Sensing Laboratory TELE, Universite Catholique de Louvain, Louvain la Neuve, Belgium
    Radiother Oncol 85:232-8. 2007
    ..To improve treatment planning in radiotherapy for non-small cell lung cancer by including Respiratory Correlated-Computed Tomography (RC-CT) information in tumour delineation and dose planning...
  85. ncbi request reprint Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study
    Dirk De Ruysscher
    Department of Radiation and Medical Oncology, Sint Maarten Ziekenhuis, Rooienberg 25, 2570 Duffel, Belgium
    Radiother Oncol 64:33-6. 2002
    ..All toxicities were reversible, with only two of ten patients experiencing grade 3 oesophagitis, no treatment-related deaths and no serious late effects...
  86. ncbi request reprint Proton therapy in clinical practice: current clinical evidence
    Michael Brada
    The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 25:965-70. 2007
  87. ncbi request reprint A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer
    Mark Lodge
    Cochrane Cancer Network, Oxford, UK
    Radiother Oncol 83:110-22. 2007
    ..In view of the continued increase in the number of hadron (i.e. neutron, proton and light or heavy ion) therapy (HT) centres we performed a systematic literature review to identify reports of the efficacy of HT...